Form 4: 89bio Director's Options Disposed in Roche Merger

89bio, Inc. Director Martin Babler's stock options were disposed of as part of the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus a CVR.

Summary

• Martin Babler, a Director of 89bio, Inc. (ETNB), reported the disposal of his stock options.
• The disposal occurred on October 30, 2025, as a result of the Agreement and Plan of Merger dated September 17, 2025, between 89bio, Inc., Roche Holdings, Inc. ('Parent'), and Bluefin Merger Subsidiary, Inc. ('Merger Sub').
• On October 30, 2025, Parent and Merger Sub completed a tender offer for all outstanding shares of 89bio common stock.
• The offer price was $14.50 per share in cash (the 'Closing Amount') plus one non-tradeable contingent value right (CVR) representing the right to receive up to an aggregate of $6.00 per share upon achievement of specified milestones.
• Following the tender offer, Merger Sub merged with and into 89bio, Inc., making 89bio a wholly-owned subsidiary of Roche Holdings, Inc.
• Immediately prior to the merger's effective time, all outstanding stock options became fully vested and exercisable.
• Unexercised options were cancelled and converted into a cash amount equal to the Closing Amount minus the exercise price, multiplied by the number of shares, plus one CVR per share.
• Options with an exercise price equal to or greater than the Closing Amount but less than $20.50 ('Out of the Money Options') were converted into the right to receive CVRs and potential future cash payments tied to milestone achievements.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment.
• Martin Babler disposed of 67,700 stock options with an exercise price of $8.86 and 56,400 stock options with an exercise price of $9.60, both on October 30, 2025.

Sentiment

Score: 7

Explanation: The completion of the merger provides immediate cash value and potential future upside via CVRs for shareholders and eligible option holders. However, the non-tradeable and contingent nature of CVRs, along with the cancellation of certain high-exercise-price options without payment, introduces some negative aspects.

Positives

• The completion of the merger provides immediate cash value for shareholders and eligible option holders.
• The inclusion of a Contingent Value Right (CVR) offers potential additional upside of up to $6.00 per share upon the achievement of specified milestones.
• All outstanding options became fully vested and exercisable prior to the merger, allowing eligible holders to realize value.

Negatives

• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment, resulting in a loss of value for those holders.
• The CVRs are non-tradeable, limiting liquidity, and their value is contingent on future milestone achievements, introducing uncertainty.
• Out of the Money Options (exercise price between $14.50 and $20.50) did not receive the initial cash payment and are solely reliant on CVR milestone payments for value.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specified milestones, which may not occur.
• The CVRs are non-tradeable, meaning holders cannot sell them for immediate liquidity.
• There is a risk that the aggregate amount of $6.00 per share from CVRs may not be fully realized if milestones are not met by their respective outside dates.

Future Outlook

89bio, Inc. is now a wholly-owned subsidiary of Roche Holdings, Inc., and its future operations and strategic direction will be integrated within Roche's broader corporate strategy. The future value for former 89bio shareholders holding CVRs depends entirely on the achievement of specified clinical and regulatory milestones.

Industry Context

This acquisition reflects a continuing trend in the biotechnology and pharmaceutical industry where larger pharmaceutical companies acquire smaller biotechs to bolster their pipelines, particularly in areas with high unmet medical needs. The use of CVRs is a common mechanism in such deals to bridge valuation gaps and share future development risks and rewards.

Comparison to Industry Standards

• The acquisition structure, combining an upfront cash payment with a contingent value right (CVR), is a common approach in biotech M&A, similar to deals like Sanofi's acquisition of Kadmon Holdings or Bristol Myers Squibb's acquisition of MyoKardia.
• The CVR component, offering up to $6.00 per share, represents a significant potential upside (approximately 41% of the cash component), which is within the typical range for such contingent payments in biotech acquisitions, often ranging from 20% to 50% of the upfront cash.
• The treatment of stock options, including full vesting upon merger and conversion into cash and/or CVRs, aligns with standard practices in corporate takeovers to ensure executive and employee alignment and compensation for their equity holdings.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $14.50 cash per share and one non-tradeable CVR per share, providing immediate liquidity and potential future value.
• Option Holders: Options were either converted into cash and CVRs, or solely CVRs (for 'Out of the Money Options'), or cancelled without payment (for options with exercise price >= $20.50), impacting their equity compensation.
• Employees: Those holding options would be impacted by the option treatment terms. The company's integration into Roche Holdings, Inc. will likely affect employment structure and culture.

Next Steps

• Monitoring the achievement of specified milestones for the Contingent Value Rights (CVRs) to determine potential future payments.

Key Dates

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Tender Offer, Stock Options, Contingent Value Right, CVR, Insider Transaction, Martin Babler